cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.17863/cam.66593
title: Research data supporting "Studying Programmer Behaviour at Scale: A Case Study Using Amazon Mechanical Turk"

description: This file contains the summary data described in the associated case study from the companion paper. The workbook contains an index sheet explaining any abbreviations, annotations, and labels used throughout the datafile, followed by a sheet with the summary data, and a sheet grouping the data by various metrics of interest. The file has been verified to open in Microsoft Excel (https://products.office.com/excel) and Libre Office (https://www.libreoffice.org)
DOI: 10.57702/mfgy7jvn
title: Multimodal Observation Dataset for Contact-Rich Manipulation Tasks

description: The dataset used in the paper is a multimodal observation dataset for contact-rich manipulation tasks.
DOI: 10.57702/fjx2xuqu
title: Multiple Sequence Alignments of TEM-1, PSE-1, and AAC6

description: The dataset used in this paper is a collection of multiple sequence alignments of naturally diverged homologs of the experimentally studied wildtype proteins TEM-1, PSE-1, and AAC6.
DOI: 10.6084/m9.figshare.23284633
title: Differences in adjuvant chemotherapy and oncological outcomes according to margin status in patients with stage III colon cancer

description: Microscopically positive margins to lymph node metastases (R1LNM) are associated with poorer oncological outcomes in patients with Stage 3 colon cancer. These poorer outcomes were seen despite a greater proportion of these patients receiving adjuvant chemotherapy when compared to those with microscopically negative (R0) margins. We sought to determine if differences in the type or duration of adjuvant chemotherapy could account for the differences in outcomes seen between patients with R0 and R1LNM margins. A multicentre retrospective study including patients undergoing surgery for Stage 3 colon cancer between 2016–2019 at specialist centres. Patients were stratified according to margins status (R0 vs R1LNM). Type/duration of chemotherapy and oncological outcomes were compared between groups. 718 patients were included, of whom 100 had R1LNM margins (13.1%). Patients with R1LNM margins had significantly poorer 3-year distant metastases-free (R0 78.2% (95% CI 74.5–81.3) versus R1LNM 58.8% (95% CI 47.2–68.6), <i>p</i> &lt; 0.001) and disease specific survival (R0 88.3% (95% CI 85.2–90.9) versus R1LNM 78.5% (95% CI 68.0–85.8), <i>p</i> &lt; 0.001) when compared to those with R0 margins. No differences were noted in the proportion of patients who completed long-course chemotherapy or were treated with oxaliplatin-based combinations between the R1LNM and R0 groups. Differences in outcomes between R0 and R1LNM groups persisted even when only those patients who completed long-course chemotherapy were compared. Differences in adjuvant chemotherapy do not appear to account for the poorer oncological outcomes seen in patients with R1LNM margins after surgery for Stage 3 colon cancer. This suggests that adjuvant chemotherapy may be less effective in this patient group. Further studies to elucidate a potential biological basis for this difference are warranted.
DOI: 10.6084/m9.figshare.23284633.v1
title: Differences in adjuvant chemotherapy and oncological outcomes according to margin status in patients with stage III colon cancer

description: Microscopically positive margins to lymph node metastases (R1LNM) are associated with poorer oncological outcomes in patients with Stage 3 colon cancer. These poorer outcomes were seen despite a greater proportion of these patients receiving adjuvant chemotherapy when compared to those with microscopically negative (R0) margins. We sought to determine if differences in the type or duration of adjuvant chemotherapy could account for the differences in outcomes seen between patients with R0 and R1LNM margins. A multicentre retrospective study including patients undergoing surgery for Stage 3 colon cancer between 2016–2019 at specialist centres. Patients were stratified according to margins status (R0 vs R1LNM). Type/duration of chemotherapy and oncological outcomes were compared between groups. 718 patients were included, of whom 100 had R1LNM margins (13.1%). Patients with R1LNM margins had significantly poorer 3-year distant metastases-free (R0 78.2% (95% CI 74.5–81.3) versus R1LNM 58.8% (95% CI 47.2–68.6), <i>p</i> &lt; 0.001) and disease specific survival (R0 88.3% (95% CI 85.2–90.9) versus R1LNM 78.5% (95% CI 68.0–85.8), <i>p</i> &lt; 0.001) when compared to those with R0 margins. No differences were noted in the proportion of patients who completed long-course chemotherapy or were treated with oxaliplatin-based combinations between the R1LNM and R0 groups. Differences in outcomes between R0 and R1LNM groups persisted even when only those patients who completed long-course chemotherapy were compared. Differences in adjuvant chemotherapy do not appear to account for the poorer oncological outcomes seen in patients with R1LNM margins after surgery for Stage 3 colon cancer. This suggests that adjuvant chemotherapy may be less effective in this patient group. Further studies to elucidate a potential biological basis for this difference are warranted.
DOI: 10.57702/luptz5t2
title: Amino Acid Sequences of TEM-1, PSE-1, and AAC6

description: The dataset used in this paper is a collection of amino acid sequences of the experimentally evolved proteins TEM-1, PSE-1, and AAC6.
DOI: 10.6084/m9.figshare.23272331
title: Survival with lung cancer in Finland has not improved during 2007–2019–a single center retrospective population-based real-world study

description: According to the CONCORD-3 study, the 5-year survival rate of lung cancer patients in Finland has not improved during the twenty-first century. In the present study, we evaluated the survival trends of lung cancer patients diagnosed and treated in one of the five university hospitals in Finland to determine possible explanatory factors behind the lack of improved survival. This retrospective population-based study included all lung cancer patients diagnosed in Tampere University Hospital in 2007–2019 (<i>N</i> = 3041). The study population was divided into two subcohorts: the patients diagnosed in 2007–2012 and those diagnosed in 2013–2019. The two subcohorts were then compared to analyze the temporal changes in survival and the distribution of prognostic factors. A comparison of the patients diagnosed in 2007–2012 and 2013–2019 showed that the patients’ overall survival had remained unchanged. The median overall survival was 8.7 months in the earlier subcohort and 9.2 months in the later subcohort. The respective 5-year survival rates were 16.6% and 17.8%, and these differences were not statistically significant. The proportion of stage IV patients (approximately 59% in both subcohorts) and their risk of death were similar for the two subcohorts. According to the regression analysis, male gender, advanced stage, and poor Eastern Cooperative Oncology Group performance status were independent risk factors for death, while a never-smoking status and mutation-positive disease were associated with a decreased risk of death, but only in the later cohort. Echoing the results of CONCORD-3, this study confirmed that the real-world survival of unselected lung cancer populations in Finland has not improved over the last 15 years, mainly because of the unchanged proportions of patients with late-stage lung cancer. This calls for earlier recognition of lung cancer, achieved by screening and increasing awareness of the disease.
DOI: 10.6084/m9.figshare.23272331.v1
title: Survival with lung cancer in Finland has not improved during 2007–2019–a single center retrospective population-based real-world study

description: According to the CONCORD-3 study, the 5-year survival rate of lung cancer patients in Finland has not improved during the twenty-first century. In the present study, we evaluated the survival trends of lung cancer patients diagnosed and treated in one of the five university hospitals in Finland to determine possible explanatory factors behind the lack of improved survival. This retrospective population-based study included all lung cancer patients diagnosed in Tampere University Hospital in 2007–2019 (<i>N</i> = 3041). The study population was divided into two subcohorts: the patients diagnosed in 2007–2012 and those diagnosed in 2013–2019. The two subcohorts were then compared to analyze the temporal changes in survival and the distribution of prognostic factors. A comparison of the patients diagnosed in 2007–2012 and 2013–2019 showed that the patients’ overall survival had remained unchanged. The median overall survival was 8.7 months in the earlier subcohort and 9.2 months in the later subcohort. The respective 5-year survival rates were 16.6% and 17.8%, and these differences were not statistically significant. The proportion of stage IV patients (approximately 59% in both subcohorts) and their risk of death were similar for the two subcohorts. According to the regression analysis, male gender, advanced stage, and poor Eastern Cooperative Oncology Group performance status were independent risk factors for death, while a never-smoking status and mutation-positive disease were associated with a decreased risk of death, but only in the later cohort. Echoing the results of CONCORD-3, this study confirmed that the real-world survival of unselected lung cancer populations in Finland has not improved over the last 15 years, mainly because of the unchanged proportions of patients with late-stage lung cancer. This calls for earlier recognition of lung cancer, achieved by screening and increasing awareness of the disease.
DOI: 10.6084/m9.figshare.23574104
title: Patient-reported outcomes after curative treatment for prostate cancer with prostatectomy, primary radiotherapy or salvage radiotherapy

description: Trials reporting adverse health outcomes (AHOs) in terms of patient-reported outcome measures (PROMs) after contemporary curative treatment of prostate cancer (PC) are hampered by study heterogeneity and lack of new treatment techniques. Particularly, the evidence regarding toxicities after radiotherapy (RT) with the volumetric arc therapy (VMAT) technique is limited, and comparisons between men treated with surgery, primary radiotherapy (PRT) and salvage radiotherapy (SRT) are lacking. The aim of the study was to evaluate change in PROMs 3 months after treatment with robotic-assisted laparoscopic prostatectomy (RALP), PRT and SRT administered with VMAT. A prospective cohort study of men with PC who received curative treatment at the University Hospital of North Norway between 2012 and 2017 for RALP and between 2016 and 2021 for radiotherapy was conducted. A cohort of 787 men were included; 406 men treated with RALP, 265 received PRT and 116 received SRT. Patients completed the validated PROM instrument EPIC-26 before (pre-treatment) and 3 months after treatment. EPIC-26 domain summary scores (DSSs) were analysed, and changes from pre-treatment to 3 months reported. Changes were deemed clinically relevant if exceeding validated minimally clinically important differences (MCIDs). Men treated with RALP reported clinically relevant declining urinary incontinence DSS (−41.7 (SD 30.7)) and sexual DSS (−46.1 (SD 30.2)). Men who received PRT reported worsened urinary irritative DSS (−5.2 (SD 19.6)), bowel DSS (−8.2 (SD 15.1)) and hormonal DSS (−9.6 (SD 18.2)). Men treated with SRT experienced worsened urinary incontinence DSS (−7.3 (SD 18.2)), urinary irritative DSS (−7.5 (SD 14.0)), bowel DSS (−12.5 (SD 16.1)), sexual DSS (−14.9 (SD 18.9)) and hormonal DSS (−23.8 (SD 20.9)). AHOs 3 months after contemporary curative treatment for PC varied according to treatment modality and worsened in all treatment groups, although most in SRT.
DOI: 10.6084/m9.figshare.23574104.v1
title: Patient-reported outcomes after curative treatment for prostate cancer with prostatectomy, primary radiotherapy or salvage radiotherapy

description: Trials reporting adverse health outcomes (AHOs) in terms of patient-reported outcome measures (PROMs) after contemporary curative treatment of prostate cancer (PC) are hampered by study heterogeneity and lack of new treatment techniques. Particularly, the evidence regarding toxicities after radiotherapy (RT) with the volumetric arc therapy (VMAT) technique is limited, and comparisons between men treated with surgery, primary radiotherapy (PRT) and salvage radiotherapy (SRT) are lacking. The aim of the study was to evaluate change in PROMs 3 months after treatment with robotic-assisted laparoscopic prostatectomy (RALP), PRT and SRT administered with VMAT. A prospective cohort study of men with PC who received curative treatment at the University Hospital of North Norway between 2012 and 2017 for RALP and between 2016 and 2021 for radiotherapy was conducted. A cohort of 787 men were included; 406 men treated with RALP, 265 received PRT and 116 received SRT. Patients completed the validated PROM instrument EPIC-26 before (pre-treatment) and 3 months after treatment. EPIC-26 domain summary scores (DSSs) were analysed, and changes from pre-treatment to 3 months reported. Changes were deemed clinically relevant if exceeding validated minimally clinically important differences (MCIDs). Men treated with RALP reported clinically relevant declining urinary incontinence DSS (−41.7 (SD 30.7)) and sexual DSS (−46.1 (SD 30.2)). Men who received PRT reported worsened urinary irritative DSS (−5.2 (SD 19.6)), bowel DSS (−8.2 (SD 15.1)) and hormonal DSS (−9.6 (SD 18.2)). Men treated with SRT experienced worsened urinary incontinence DSS (−7.3 (SD 18.2)), urinary irritative DSS (−7.5 (SD 14.0)), bowel DSS (−12.5 (SD 16.1)), sexual DSS (−14.9 (SD 18.9)) and hormonal DSS (−23.8 (SD 20.9)). AHOs 3 months after contemporary curative treatment for PC varied according to treatment modality and worsened in all treatment groups, although most in SRT.
DOI: 10.6084/m9.figshare.23560627
title: In silico comparison of whole pelvis intensity-modulated photon versus proton therapy for the postoperative management of prostate cancer

description: Limited data exist comparing intensity-modulated photon (IMRT) and proton (IMPT) radiation therapy when treating the prostate bed and pelvic lymph nodes in the postoperative setting for prostate cancer. The aim of this study was to evaluate dosimetric differences between IMRT and IMPT when treating with whole pelvis radiation therapy (WPRT) postoperatively. IMRT and IMPT plans were generated for 10 post-prostatectomy patients treated between July and August 2020. The prescription was 50 Gy radiobiologic equivalent (GyE) (proton radiobiological effective dose 1.1) to the pelvis and 70 GyE to the prostate bed in 2 GyE per fraction. Paired 2-sided Wilcoxon signed-rank tests were used to compare clinical target volume (CTV) coverage and dose to organs at risk (OARs). CTV coverage was met for all plans with 99% of CTVs receiving ≥99% of prescription doses. Dose to OARs was significantly higher with IMRT than IMPT for the following endpoints: bladder V5-V65; bowel V5-V45; sigmoid V5-V50; rectum V5-V70; femoral head V40 and maximum dose; bone V5-V65. Select endpoints with significant differences included bladder V30 (63.5 vs. 44.4%, <i>p</i> &lt; .001), bowel V15 (949 vs. 191 cc, <i>p</i> = .001) and V30 (386 vs. 121 cc, <i>p</i> &lt; .001), rectum V40 (81.8 vs. 32.1%, <i>p</i> &lt; .001) and V50 (47.6 vs. 24.9%, <i>p</i> &lt; .001), femoral head maximum doses (46.4–47.1 vs. 38.3–38.6GyE, <i>p</i> &lt; .001), and bone V10 (93.3 vs. 85.4%, <i>p</i> &lt; . 001). Mean doses for all OARs were significantly higher with IMRT, including bladder (41.9 vs. 29.7GyE, <i>p</i> &lt; .001), bowel (21.2 vs. 5.5GyE, <i>p</i> &lt; .001), and rectum (50.8 vs. 27.3GyE, <i>p</i> &lt; .001). Integral dose to ‘Body – CTV’ was significantly higher with IMRT (32.8 vs. 18.4 J, <i>p</i> &lt; .001). IMPT provides comparable target coverage to IMRT when treating prostate cancer with WPRT in the postoperative setting while significantly reducing dose to OARs. These data can inform the future clinical management and delivery of post-prostatectomy irradiation for prostate cancer.
DOI: 10.6084/m9.figshare.23560627.v1
title: In silico comparison of whole pelvis intensity-modulated photon versus proton therapy for the postoperative management of prostate cancer

description: Limited data exist comparing intensity-modulated photon (IMRT) and proton (IMPT) radiation therapy when treating the prostate bed and pelvic lymph nodes in the postoperative setting for prostate cancer. The aim of this study was to evaluate dosimetric differences between IMRT and IMPT when treating with whole pelvis radiation therapy (WPRT) postoperatively. IMRT and IMPT plans were generated for 10 post-prostatectomy patients treated between July and August 2020. The prescription was 50 Gy radiobiologic equivalent (GyE) (proton radiobiological effective dose 1.1) to the pelvis and 70 GyE to the prostate bed in 2 GyE per fraction. Paired 2-sided Wilcoxon signed-rank tests were used to compare clinical target volume (CTV) coverage and dose to organs at risk (OARs). CTV coverage was met for all plans with 99% of CTVs receiving ≥99% of prescription doses. Dose to OARs was significantly higher with IMRT than IMPT for the following endpoints: bladder V5-V65; bowel V5-V45; sigmoid V5-V50; rectum V5-V70; femoral head V40 and maximum dose; bone V5-V65. Select endpoints with significant differences included bladder V30 (63.5 vs. 44.4%, <i>p</i> &lt; .001), bowel V15 (949 vs. 191 cc, <i>p</i> = .001) and V30 (386 vs. 121 cc, <i>p</i> &lt; .001), rectum V40 (81.8 vs. 32.1%, <i>p</i> &lt; .001) and V50 (47.6 vs. 24.9%, <i>p</i> &lt; .001), femoral head maximum doses (46.4–47.1 vs. 38.3–38.6GyE, <i>p</i> &lt; .001), and bone V10 (93.3 vs. 85.4%, <i>p</i> &lt; . 001). Mean doses for all OARs were significantly higher with IMRT, including bladder (41.9 vs. 29.7GyE, <i>p</i> &lt; .001), bowel (21.2 vs. 5.5GyE, <i>p</i> &lt; .001), and rectum (50.8 vs. 27.3GyE, <i>p</i> &lt; .001). Integral dose to ‘Body – CTV’ was significantly higher with IMRT (32.8 vs. 18.4 J, <i>p</i> &lt; .001). IMPT provides comparable target coverage to IMRT when treating prostate cancer with WPRT in the postoperative setting while significantly reducing dose to OARs. These data can inform the future clinical management and delivery of post-prostatectomy irradiation for prostate cancer.
DOI: 10.57702/84bndmnh
title: Experimental Evolution Data for TEM-1, PSE-1, and AAC6

description: The dataset used in this paper is a collection of experimental evolution data for the proteins TEM-1, PSE-1, and AAC6.
DOI: 10.6084/m9.figshare.23640981
title: The BioLymph study – implementing precision medicine approaches in lymphoma diagnostics, treatment and follow-up: feasibility and first results

description: The BioLymph study – implementing precision medicine approaches in lymphoma diagnostics, treatment and follow-up: feasibility and first results
DOI: 10.6084/m9.figshare.23640981.v2
title: The BioLymph study – implementing precision medicine approaches in lymphoma diagnostics, treatment and follow-up: feasibility and first results

description: The BioLymph study – implementing precision medicine approaches in lymphoma diagnostics, treatment and follow-up: feasibility and first results
DOI: 10.6084/m9.figshare.23668129
title: Calcium electroporation as an adjunct therapy for pembrolizumab-resistant bladder cancer: a case report

description: Calcium electroporation as an adjunct therapy for pembrolizumab-resistant bladder cancer: a case report
DOI: 10.6084/m9.figshare.23668129.v1
title: Calcium electroporation as an adjunct therapy for pembrolizumab-resistant bladder cancer: a case report

description: Calcium electroporation as an adjunct therapy for pembrolizumab-resistant bladder cancer: a case report
DOI: 10.6084/m9.figshare.23688808.v1
title: High-intensity interval training and thromboembolic events during chemotherapy for testicular cancer: a retrospective analysis from the <i>Body & Cancer</i> cohort

description: <b>Background:</b> Men with testicular cancer receiving platinum-based chemotherapy have an increased risk of thromboembolic events, with incidence rates between 8–24%. A recent trial evaluating the effect of high-intensity interval training (HIIT) prematurely closed as three out of nine participants (33%) in the intervention group developed a thromboembolic event. The purpose of this retrospective cohort study was: 1) (primary) to evaluate the incidence of thromboembolic events in men receiving chemotherapy for testicular cancer who had participated in HIIT during a 6-week exercise program (<i>Body & Cancer)</i> 2) to describe the feasibility of this program. <b>Material and methods:</b> Forty men who had participated in at least one HIIT session from February 2007 to February 2020 were included. Electronic medical records were searched for incident thromboembolic events (arterial and venous) during <i>Body & Cancer</i> and up to one-year post-chemotherapy. Attendance, cardiorespiratory fitness (VO<sub>2</sub>-peak), and upper and lower extremity muscular strength (1 repetition maximum (RM)) were obtained from the <i>Body & Cancer</i> database. <b>Results:</b> One participant developed a thromboembolic event during <i>Body & Cancer</i>. No participants developed a thromboembolic event in the follow-up period. In all, data represent 160 HIIT sessions with a median attendance of eight sessions [range 1–19]. Statistically significant increases in upper and lower extremity strength were observed (8.6 (4.2 to 13.0) and 26.0 (14.9 to 37.0) kg, respectively). No significant increase in cardiorespiratory fitness was found (0.14 (−0.03 to 0.31) l/min). <b>Conclusion:</b> While conclusions on the safety of HIIT cannot be drawn, data from the present study do not support previous findings cautioning avoidance of HIIT due to a possible added risk of thromboembolic events in men receiving platinum-based chemotherapy for testicular cancer. Considering the potential for positive effects on cardiovascular outcomes associated with HIIT, future studies with robust design should be performed in this population to confirm these observations.